牛牛AI助理已提取核心訊息
On January 8, 2024, Novavax, Inc. updated investors, reaffirming its guidance for the full year 2023 expenses to be between $1.15 billion and $1.25 billion. The company is currently finalizing its financial results for the year ended December 31, 2023, and has stated that the preliminary financial data provided is based on the information available and may be subject to change. The data has not been audited or reviewed by Ernst & Young LLP, the company's independent registered public accounting firm, or any other independent accountants. Novavax cautions that the actual results may differ materially from the preliminary data and advises investors not to place undue reliance on this preliminary information. Additionally, Novavax presented strategic and business updates at the 42nd Annual J.P. Morgan Healthcare Conference, with the presentation available on the company's website. The company also included forward-looking statements in its report and presentation, warning that actual results could vary significantly due to various risks and uncertainties.
On January 8, 2024, Novavax, Inc. updated investors, reaffirming its guidance for the full year 2023 expenses to be between $1.15 billion and $1.25 billion. The company is currently finalizing its financial results for the year ended December 31, 2023, and has stated that the preliminary financial data provided is based on the information available and may be subject to change. The data has not been audited or reviewed by Ernst & Young LLP, the company's independent registered public accounting firm, or any other independent accountants. Novavax cautions that the actual results may differ materially from the preliminary data and advises investors not to place undue reliance on this preliminary information. Additionally, Novavax presented strategic and business updates at the 42nd Annual J.P. Morgan Healthcare Conference, with the presentation available on the company's website. The company also included forward-looking statements in its report and presentation, warning that actual results could vary significantly due to various risks and uncertainties.
2024年1月8日，Novavax, Inc.向投資者通報了最新情況，重申其2023年全年支出在11.5億美元至12.5億美元之間的指導方針。該公司目前正在敲定截至2023年12月31日的年度的財務業績，並表示提供的初步財務數據基於現有信息，可能會發生變化。該數據未經過安永會計師事務所、該公司的獨立註冊會計師事務所或任何其他獨立會計師的審計或審查。Novavax警告說，實際業績可能與初步數據存在重大差異，並建議投資者不要過分依賴這些初步信息。此外，Novavax在第42屆摩根大通醫療保健年度會議上介紹了戰略和業務最新情況，該演講可在公司網站上公佈。該公司還在其報告和陳述中納入了前瞻性陳述，警告說，由於各種風險和不確定性，實際業績可能會有很大差異。
2024年1月8日，Novavax, Inc.向投資者通報了最新情況，重申其2023年全年支出在11.5億美元至12.5億美元之間的指導方針。該公司目前正在敲定截至2023年12月31日的年度的財務業績，並表示提供的初步財務數據基於現有信息，可能會發生變化。該數據未經過安永會計師事務所、該公司的獨立註冊會計師事務所或任何其他獨立會計師的審計或審查。Novavax警告說，實際業績可能與初步數據存在重大差異，並建議投資者不要過分依賴這些初步信息。此外，Novavax在第42屆摩根大通醫療保健年度會議上介紹了戰略和業務最新情況，該演講可在公司網站上公佈。該公司還在其報告和陳述中納入了前瞻性陳述，警告說，由於各種風險和不確定性，實際業績可能會有很大差異。
有用
沒用